Breathe最新文献 - Book学术

Summary for clinicians: ERS guidelines on pulmonary alveolar proteinosis. 临床总结：肺泡蛋白沉积症的ERS指南。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0224-2024

Tiago Alfaro, Cormac McCarthy, Francesco Bonella, Elisabeth Bendstrup, Marissa O'Callaghan

引用次数: 0

Lung transplantation for interstitial lung disease. 肺移植治疗间质性肺疾病。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0169-2024

Nicola J Ronan, Feargal Helly, Michelle A Murray

{"title":"Lung transplantation for interstitial lung disease.","authors":"Nicola J Ronan, Feargal Helly, Michelle A Murray","doi":"10.1183/20734735.0169-2024","DOIUrl":"10.1183/20734735.0169-2024","url":null,"abstract":"Interstitial lung diseases (ILDs) are now the most common indication for lung transplant internationally. Given that many lung transplant candidates with idiopathic pulmonary fibrosis are older, referral to a pulmonary rehabilitation programme is important to help mitigate the adverse outcomes associated with frailty. Despite this increase many patients with ILD who would potentially benefit from lung transplant are either not referred or referred too late. Particularly relevant in ILD which may have prominent extra-pulmonary manifestations is a multidisciplinary assessment of comorbidities which may impact on post lung transplant outcomes. Particular challenges in lung transplant for ILD are increasing age, comorbidities, donor lung sizing and the risk-benefit balance of single versus bilateral lung transplant. Evidence is continuing to evolve for lung transplant in rarer ILDs, including surfactant protein associated ILD and TERT mutations. Unfortunately, the number of potential lung transplant recipients exceeds available donor organs and some patients will die without transplant. Palliative care is an important aspect of managing patients on an active lung transplant list to help optimise physical and psychological symptoms associated with uncertainty on an active lung transplant list.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 2","pages":"240169"},"PeriodicalIF":2.3,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Our journey with pulmonary fibrosis: from challenges to change. 我们的肺纤维化之旅：从挑战到改变。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0008-2025

Clive Green, Sue Green, Lucy Robinson

引用次数: 0

How to move towards more sustainable asthma care in Europe: an expert opinion paper. 如何在欧洲实现更可持续的哮喘护理：一份专家意见文件。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0229-2024

Christer Janson, Alex Wilkinson, Hanna Hisinger-Mölkänen, Bernardino Alcázar Navarrete, Kai-Michael Beeh, Federico Lavorini, Hannu Kankaanranta, John Pritchard, Charlotte Suppli Ulrik, Aarti Bansal, Satu Lähelmä, Lauri Lehtimäki

引用次数: 0

An update on diagnosis and treatments of childhood interstitial lung diseases. 儿童间质性肺疾病的诊断和治疗进展。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0004-2025

Honorata Marczak, Katarzyna Krenke, Matthias Griese, Julia Carlens, Elias Seidl, Carlee Gilbert, Nagehan Emiralioglu, Alba Torrent-Vernetta, Brigitte Willemse, Ralph Epaud, Celine Delestrain, Camille Louvrier, Václav Koucký, Nadia Nathan

{"title":"An update on diagnosis and treatments of childhood interstitial lung diseases.","authors":"Honorata Marczak, Katarzyna Krenke, Matthias Griese, Julia Carlens, Elias Seidl, Carlee Gilbert, Nagehan Emiralioglu, Alba Torrent-Vernetta, Brigitte Willemse, Ralph Epaud, Celine Delestrain, Camille Louvrier, Václav Koucký, Nadia Nathan","doi":"10.1183/20734735.0004-2025","DOIUrl":"10.1183/20734735.0004-2025","url":null,"abstract":"Childhood interstitial lung diseases (chILDs) are rare and heterogeneous disorders associated with significant morbidity and mortality. The clinical presentation of chILD typically includes chronic or recurrent respiratory signs and symptoms with diffuse radiographic abnormalities on chest imaging. Diagnosis requires a structured, multi-step approach. Treatment options are limited, with disease-specific therapies available only in selected cases and management relying primarily on supportive care. Awareness of chILDs has been steadily increasing. New diagnoses, advanced diagnostic tests, and novel treatments are emerging each year, highlighting the importance of collaborative, multidisciplinary teams in providing comprehensive care for children and families affected by these complex conditions. On behalf of the European Respiratory Society Clinical Research Collaboration for chILD (ERS CRC chILD-EU), this review provides an updated overview of the diagnostic approach and management strategies for chILDs.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 2","pages":"250004"},"PeriodicalIF":2.3,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into interstitial lung disease pathogenesis. 对间质性肺疾病发病机制的认识。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0261-2024

Eirini Vasarmidi, Julie C Worrell, Irma Mahmutovic Persson, Naheem Yaqub, Ewa Miądlikowska, Cindy Barnig, Agnes Boots, Niki L Reynaert, Sara Cuevas Ocaña

{"title":"Insights into interstitial lung disease pathogenesis.","authors":"Eirini Vasarmidi, Julie C Worrell, Irma Mahmutovic Persson, Naheem Yaqub, Ewa Miądlikowska, Cindy Barnig, Agnes Boots, Niki L Reynaert, Sara Cuevas Ocaña","doi":"10.1183/20734735.0261-2024","DOIUrl":"10.1183/20734735.0261-2024","url":null,"abstract":"This review summarises some of the key features of interstitial lung diseases (ILDs) from a translational science point of view and brings insights into potential therapeutic options. Genetic predisposition and environmental factors like smoking, pollution and infections significantly impact the onset, progression and treatment response in ILDs, highlighting the need for personalised management. Fibroblasts are central to ILD pathology, influencing the tissue microenvironment, immune cell interactions and extracellular matrix (ECM) production, making them critical therapeutic targets. Monocyte-derived M2 macrophages drive fibrosis in idiopathic pulmonary fibrosis by secreting cytokines and remodelling the ECM. Understanding macrophage subtypes and their dynamics offers new therapeutic possibilities. Chronic type 2 immunity contributes to fibrosis, emphasising the need to enhance protective markers in order to even out the balance shift of pathological immune responses in ILD treatments. Serum biomarkers like Krebs von den Lungen-6 (KL-6), surfactant protein (SFTP) D, matrix metalloproteinase-7 (MMP-7), and C-C motif chemokine ligand (CCL)-18 are valuable for diagnosing and predicting ILD progression, although more research is needed for clinical application. Animal models, especially bleomycin-based models, offer insights into ILD pathology, but challenges like lung hyperinflation highlight the need for careful model selection and translational research to bridge preclinical and clinical findings.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 2","pages":"240261"},"PeriodicalIF":2.3,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asbestos and benign pleural diseases: a narrative review. 石棉与良性胸膜疾病：叙述性回顾。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0236-2024

Lucía Ferreiro, María E Toubes, Nuria Rodríguez-Núñez, Luis Valdés

引用次数: 0

The use of forced oscillation technique in children with restrictive physiology. 强迫振荡技术在限制性生理患儿中的应用。

IF 2.3

Breathe Pub Date : 2025-05-13 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0106-2024

Andre Gie, Ruan Swanepoel, Marieke M van der Zalm, Pierre Goussard

引用次数: 0

Interstitial lung diseases. 肺间质性疾病。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0169-2025

Imran Sulaiman

引用次数: 0

The lung microbiome in interstitial lung disease. 肺间质性疾病的肺微生物组。

IF 2.3

Breathe Pub Date : 2025-04-17 eCollection Date: 2025-04-01 DOI: 10.1183/20734735.0167-2024

Sheridan G Mikhail, David N O'Dwyer

{"title":"The lung microbiome in interstitial lung disease.","authors":"Sheridan G Mikhail, David N O'Dwyer","doi":"10.1183/20734735.0167-2024","DOIUrl":"https://doi.org/10.1183/20734735.0167-2024","url":null,"abstract":"Interstitial lung disease (ILD) is a heterogeneous chronic form of lung disease. The pathogenesis of ILD is poorly understood and a common form of ILD, idiopathic pulmonary fibrosis (IPF) is associated with poor prognosis. There is evidence for substantial dysregulated immune responses in ILD. The microbiome is a key regulator of the immune response, and the lung microbiome correlates with alveolar immunity and clinical outcomes in ILD. Most observational lung microbiome studies have been conducted in patients with IPF. A consistent observation in these studies is that the bacterial burden of the lung is elevated in patients with IPF and predicts mortality. However, our understanding of the mechanism is incomplete and our understanding of the role of the lung microbiome in other forms of ILD is limited. The microbiomes of the oropharynx and gut may have implications for the lung microbiome and pulmonary immunity in ILD but require substantial further research. Here, we discuss the studies supporting a role for the lung microbiome in the pathogenesis of IPF, and briefly describe the putative role of the oral-lung axis and the gut-lung axis in ILD.","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"21 2","pages":"240167"},"PeriodicalIF":2.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0